Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 3Breast Neoplasms 3Neoplasms 2Biliary Tract Neoplasms 2Ovarian Neoplasms 1HER2-expressing Cancers 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignancies 1

Interventions

zanidatamab 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HER2-expressing Cancers × zanidatamab × Clear all
NCT05027139 2025-10-16

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Jazz Pharmaceuticals

Phase 1/2 Completed
52 enrolled

HER2-expressing Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡